Accelerating Breakthrough Discoveries into Medicines

Ferozrpapa from OptiKira talking in a lab

Scientists in lab examining solution

From research institutions to patients

BioMotiv is the mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals Cleveland Medical Center. The company’s focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.

Led by experienced industry professionals

BioMotiv has a capable and connected management team, advisory board, and Board that oversee the development, funding, active management, and partnering of the portfolio of therapeutic products.

Pharmaceutical Expertise

Our leadership and portfolio teams are well-versed in translational science, with deep pharmaceutical experience having supported the advancement of numerous programs into clinical development and into the marketplace.

Deep Business Networks

Through their careers, the company’s leadership team and advisory board members have developed broad relationships in the investment and pharmaceutical industries that are available to be accessed by BioMotiv companies.

Partnered with leading companies

Working with
The Harrington Project
to bridge the Valley of Death


Nature Features Sujana’s Technology

CLEVELAND, June 5, 2017 – Nature Communications has published the research of Daniel I. Simon, M.D.; Edward Plow, Ph.D.; and Yunmei Wang, Ph.D. – Founders of Sujana Biotech – which describes a novel target for thrombotic disorders that does not...

Cell Features OptiKira’s Technology for Reversing Diabetes

CLEVELAND, April 26, 2017 – OptiKira founders Dr. Feroz Papa (UCSF), Dr. Bradley Backes (UCSF), and Dr. Dustin Maly (University of Washington) have published research showing that direct targeting of IRE1α, using mono-selective KIRA8, reverses autoimmune...

Takeda, HDI Partner to Advance Rare Diseases Treatments

Harrington Discovery Institute (HDI) and Takeda Pharmaceuticals have teamed up to support the translation of research into treatments for rare diseases. The alliance builds on HDI’s model and results in a dedicated rare-disease funding track that will benefit from...